Fate Therapeutics Aktie
1,76
EUR
-0,04
EUR
-2,39
%
2,07
USD
+0,13
USD
+6,43
%
Fate Therapeutics jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Werbung
Fate Therapeutics Aktie Analyse
| 09.08.19 | Fate Therapeutics Buy | BTIG Research | |
| 22.07.19 | Fate Therapeutics Overweight | Cantor Fitzgerald | |
| 12.07.19 | Fate Therapeutics Outperform | Oppenheimer & Co. Inc. | |
| 06.03.18 | Fate Therapeutics Neutral | H.C. Wainwright & Co. | |
| 12.10.17 | Fate Therapeutics Buy | H.C. Wainwright & Co. | |
| 08.11.16 | Fate Therapeutics Outperform | Wedbush Morgan Securities Inc. | |
| 15.04.16 | Fate Therapeutics Outperform | BMO Capital Markets | |
| 11.05.15 | Fate Therapeutics Buy | H.C. Wainwright & Co. | |
|
Werbung
|
|||
Werbung
Werbung